Alto Neuroscience (ANRO) to Release Quarterly Earnings on Thursday

Alto Neuroscience (NYSE:ANRO) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Alto Neuroscience Stock Up 10.6%

NYSE:ANRO opened at $23.09 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The firm has a market cap of $717.38 million, a P/E ratio of -10.08 and a beta of 2.52. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $23.56. The firm has a 50-day simple moving average of $17.61 and a two-hundred day simple moving average of $12.76.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ANRO. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Robert W. Baird upped their price target on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. BTIG Research lifted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Finally, Chardan Capital lifted their price target on shares of Alto Neuroscience from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average price target of $26.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANRO. AQR Capital Management LLC purchased a new position in shares of Alto Neuroscience during the first quarter valued at approximately $52,000. Invesco Ltd. purchased a new position in Alto Neuroscience during the 1st quarter valued at $67,000. Bridgeway Capital Management LLC grew its position in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in Alto Neuroscience in the fourth quarter worth $198,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Alto Neuroscience in the fourth quarter worth $221,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.